78671results about "Fermentation" patented technology

The invention discloses a method for preparing diglyceride with the effects of reducing blood fat, total cholesterol, blood sugar and uric acid through enzymolysis and a product and application of the diglyceride, and belongs to the technical field of diglyceride production.The method comprises the following steps that 1, vegetable oil, glycerin, compound lipase and water are mixed to be subjected to a glycerolysis reaction, and a reactant is obtained; (2) separating reactants, and collecting supernatant; (3) performing distillation separation on the supernatant, and performing decoloration and deodorization to obtain diglyceride; the vegetable oil in the step (1) is low-erucic acid rapeseed oil and corn oil; the composite lipase in the step (1) is prepared from mucor javanicus lipase, aspergillus niger lipase and aspergillus oryzae lipase in a mass ratio of (2-4): 1: (5-8). According to the invention, the use amount of enzyme can be reduced, the cost is reduced, and the prepared diglyceride has better activity of reducing blood fat, total cholesterol, blood sugar and uric acid, and has more advantages in the preparation of health care products.

The invention provides an anti-human serum albumin nano antibody and application thereof, and belongs to the technical field of antibodies. The invention provides an anti-human serum albumin nano antibody HSA-32 with relatively high affinity, and the anti-human serum albumin nano antibody HSA-32 is subjected to humanized transformation, so that three obtained humanized anti-human serum albumin nano antibodies can be used for reducing the immunogenicity of the HSA-32 and improving the immunogenicity of the HSA-32; and high specificity and high affinity of combination with the human serum albumin and stability and solubility of the antibody are maintained. The anti-human serum albumin nano antibody can be used for separation, purification and detection of human serum albumin and separation and purification of polypeptide, protein or antibody drugs fused with the anti-human serum albumin nano antibody. Meanwhile, the anti-human serum albumin nano-antibody can effectively prolong the half-life period of polypeptide, protein and antibody drugs fused with the anti-human serum albumin nano-antibody, and can be used for developing long-acting polypeptide, protein or antibody drugs.

To provide VHH-containing polypeptides that bind CD123, and a method for treating cancer that includes administration of the VHH-containing polypeptides.SOLUTION: Provided is a polypeptide comprising at least one VHH domain that binds to CD123, comprising CDR1, CDR2, and CDR3, each comprising a specific amino acid sequence.SELECTED DRAWING: Figure 3A

To provide methods for treating a subject having or at risk of developing a neurocognitive disorder, such as frontotemporal lobar degeneration or neuronal ceroid lipofuscinosis.SOLUTION: Provided is a method comprising administering, to a subject diagnosed as having a neurocognitive disorder (NCD), a composition comprising a population of cells comprising a transgene encoding a progranulin (PGRN) or a granulin (GRN).SELECTED DRAWING: Figure 1A

To provide a medicine for treating a disease in a mammal.SOLUTION: Provided is a medicine for treating a disease in a mammal, comprising an expression cassette that is a first expression cassette comprising a chimeric gene operably linked to a first expression control element, the chimeric gene comprising a first portion comprising a minigene having an alternatively spliced exon and a second portion encoding a first RNA encoding a protein, the first portion being 5' to the second portion, the second portion lacking an initiation codon or start codon, the alternatively spliced exon comprising a translation initiation regulatory sequence, expression of the protein being controlled by inclusion of the alternatively spliced exon, and the medicine being used in combination with a small molecule splicing modifier that modulates splicing of the alternatively spliced exon.SELECTED DRAWING: Figure 1

A recombinant humanized collagen and a preparation method therefor. The recombinant humanized type III collagen can be efficiently and stably expressed in three expression systems of yeast, Escherichia coli, and CHO cells, and has the biological activity superior to that of a commercially available collagen product. The recombinant humanized type III collagen has structural characteristics and functional activity similar to those of a natural collagen, and thus has wide application prospects in biomedical materials, tissue engineering products, cosmetics, foods, health care products or drugs, medical instruments, medical cosmetology and the like.

The present invention discloses a human serum albumin-targeting nanobody and its application. A variety of human serum albumin-targeting nanobodies that can be used to construct long-acting fusion protein drugs and their immune screening methods are disclosed. The antibody is composed only of the heavy chain variable region and can be fused and expressed with therapeutic proteins or polypeptide drugs such as interleukin, interferon, and tumor necrosis factor in an Escherichia coli expression system. The fusion protein has the activity of specifically binding to human serum albumin, has a relatively high affinity, can effectively extend the drug half-life, and does not affect the biological activity of the recombinant protein drug at the same time.

The present invention particularly relates to a Lactiplantibacillus plantarum strain having a weight-reducing function, a live bacterium formulation, a preparation method therefor, and the use thereof. The Lactiplantibacillus plantarum strain is preserved in China General Microbiological Culture Collection Center (CGMCC) of China Committee for Culture Collection of Microorganisms, the accession number thereof being CGMCC No. 25683. The Lactiplantibacillus plantarum strain and the live bacterium formulation thereof can inhibit the growth of an obesity bacterial strain Enterobacter cloacae, reduce the cholesterol, and inhibit the differentiation of 3T3-L1 preadipocytes, so as to reduce the body weight of an obesity model mouse and reduce the total weight gain and total food utilization rate of an obesity model rat, thereby achieving an excellent weight-reducing function.

The invention belongs to the technical field of microorganisms, and particularly relates to recombinant escherichia coli containing a PDRN sequence and a preparation method thereof, and the preparation method comprises the following steps: S1, preparing a PDRN solution; s2, complementing the double strands of the PDRN into blunt ends; s3, constructing a recombinant plasmid; s4, carrying out mixed culture on a product obtained in the step S3 and escherichia coli DH5alpha; s5, screening the recombinants; s6, carrying out PCR (Polymerase Chain Reaction) amplification, and recording a strain from a fragment with the length of more than 200bp; s7, preparing a seed solution by adopting the strain prepared in the step S6; s8, strain fermentation; and S9, centrifugally collecting thalli. The method comprises the following steps: constructing a recombinant plasmid containing a PDRN fragment, introducing the recombinant plasmid into Escherichia coli, subsequently culturing the recombinant Escherichia coli to copy DNA in the Escherichia coli, extracting a purified exogenous gene fragment to obtain a strain containing a single fragment PDRN sequence, and getting rid of dependence on raw materials during subsequent extraction.

The present invention belongs to the technical field of immunology, and in particular, relates to a humanized nanoantibody against TNF-α and its application. The present invention provides a humanized nanoantibody against TNF-α, and a recombinant humanized nanoantibody against TNF-α prepared by expressing the gene of the humanized nanoantibody against TNF-α. The humanized nanoantibody against TNF-α prepared by the present invention can specifically recognize the TNF-α antigen, thereby accurately targeting the inflammatory site, reducing nonspecific reactions, and improving the therapeutic effect.

The invention belongs to the technical field of gene engineering, and particularly relates to a beta-glycosidase SS-BGL mutant for preparing rare ginsenosides and application of the beta-glycosidase SS-BGL mutant. The beta-glycosidase SS-BGL mutant is obtained by conducting single-site mutation or double-site mutation on beta-glycosidase SS-BGL with the amino acid sequence shown as SEQ ID NO.1. The beta-glycosidase SS-BGL mutant is obtained by conducting single-site mutation or double-site mutation on beta-glycosidase SS-BGL with the amino acid sequence shown as SEQ ID NO.2. Wherein the single site mutation is that phenylalanine at the 229 site of SEQ ID NO. 1 is mutated into proline; the double-site mutation is as follows: phenylalanine at the 229 site in SEQ ID NO. 1 is mutated into proline, and glycine at the 301 site is mutated into proline; or the phenylalanine at the 229 site in SEQ ID NO. 1 is mutated into proline, and the leucine at the 337 site is mutated into valine; or the phenylalanine at the 229 site in SEQ ID NO. 1 is mutated into the proline, and the glycine at the 338 site is mutated into the proline. On the basis of natural beta-glycosidase SS-BGL, the molecular structure of the beta-glycosidase SS-BGL is modified through site-directed mutagenesis, and four beta-glycosidase SS-BGL mutants with the saponin conversion activity improved are obtained.

The invention belongs to the technical field of cosmetics, and discloses anti-aging recombinant collagen as well as a preparation method and application thereof. The amino acid sequence of the anti-aging recombinant collagen is as shown in SEQ ID NO.1, and the nucleotide sequence of the anti-aging recombinant collagen is as shown in SEQ ID NO.2. The recombinant collagen CaI1 is constructed and expressed by recombining the effective sequences of the I-type collagen, the III-type collagen and the XVII-type collagen, and the recombinant collagen CaI1 is free of cytotoxicity, free of hidden danger of endotoxin and good in safety. The skin care product added with the recombinant collagen CaI1 can promote skin collagen absorption, inhibit skin aging and improve skin elasticity, and has a good application prospect.

The invention relates to the field of preparation and application of biological peptides, in particular to a hippocampal swelling peptide and application thereof in preparation of functional products for repairing male reproductive system injury. A green controllable enzymolysis technology is utilized to obtain protein polypeptide with nutritional, health-care and medicinal values, five active peptide sequences with high biological activity are obtained through further research on the basis, the high-purity active peptide is obtained through a chemical synthesis mode, and the biological activity of the peptide is verified through mouse spermatogonium.

The present invention belongs to the technical field of immunology, and specifically relates to a humanized nano antibody against IL-6, and a recombinant vector and application thereof. The present invention analyzes the screened anti-IL-6 nano antibody 4G10 sequence, and for screening the heavy chain of IL-6, the anti-IL-6 nano antibody 4G10 includes a framework region FR and an antigenic determinant complementary CDR, and the CDR1, CDR2, and CDR3 regions of the screened anti-IL-6 nano antibody 4G10 sequence are transplanted into the humanized hs2dAb skeleton to obtain the humanized nano antibody 4G10 against IL-6 of the present application; the recombinant nano antibody expressed by the gene encoding the humanized nano antibody 4G10 against IL-6 and the His tag gene fusion can specifically recognize the IL-6 antigen, and can be applied to the molecular diagnosis of autoimmune diseases and tumors and the preparation of autoimmune diseases and anti-tumor drugs.

The invention discloses a bovine serum albumin combined nano antibody and a preparation method and application thereof, the amino acid sequence of the bovine serum albumin combined nano antibody Nb1 is shown as SEQ.ID No.1, the nano antibody Nb not only has high affinity to bovine serum albumin, but also has good binding activity to both human serum albumin and mouse serum albumin, and the nano antibody Nb has high affinity to human serum albumin and mouse serum albumin. And the antibody has a relatively good broad-spectrum application range, and can be widely applied to the aspects of drug half-life period enhancement, tumor targeted therapy and imaging, immunodetection or diagnosis, recombinant albumin purification or enrichment and the like.

An automatic material supplementing method based on a real-time dynamic measurement result, the method comprising: collecting a real-time dynamic measurement result, and calculating a change rate of each component within a unit time, wherein the change rate is a consumption rate or a generation rate; selecting a component having the highest change rate as a marker within a current time period; collecting historical measurement data, and calculating a cell growth rate in a logarithmic growth phase and a target product expression rate in a cultivation and harvesting stage; taking, as a set component concentration value within the current time period of the logarithmic growth phase, a concentration level of the marker when the cell growth rate in the logarithmic growth phase is the highest; taking, as a set component concentration value within the current time period of the cultivation and harvesting stage, a concentration level of the marker when the target product expression rate in the cultivation and harvesting stage is the highest; and calculating an addition dosage of the marker within the current time period on the basis of the change rate of the marker and / or the difference between a real-time measured concentration of the marker within the current time period and the set component concentration value within the current time period, and calculating an addition dosage of a culture medium on the basis of the addition dosage of the marker, so as to obtain a material supplementing strategy.

The invention belongs to the technical field of biology, and particularly discloses a methyltransferase mutant high-throughput screening method, a methyltransferase mutant and application. The method can be used for high-throughput screening of methyltransferase mutants, the transformation efficiency of methyltransferase is improved, and high-activity methyltransferase mutants are obtained; the methyltransferase mutant provided by the invention can obviously improve the activity of methyltransferase, and is used for producing Nacetyl-5-methoxytryptamine to improve the yield. The activity of the methyltransferase can be remarkably improved by using the engineering bacterium expressing the methyltransferase mutant, the engineering bacterium is used for producing Nacetyl-5-methoxytryptamine to improve the yield, and the yield of the Nacetyl-5-methoxytryptamine is up to 22.7 mM.

The invention discloses a preparation method of yak bone collagen peptide for increasing bone mineral density and the yak bone collagen peptide. The invention provides a preparation method of yak bone collagen peptide for increasing bone mineral density. The preparation method comprises the following steps: providing yak bone powder; mixing the yak bone meal with a phosphate buffer solution, adjusting the pH value to 5-5.5, mixing with compound bacteria, and carrying out demineralization treatment to obtain a demineralized product; mixing the demineralized product with a compound enzyme, and carrying out an enzymolysis reaction to obtain an enzymolysis product; heating, centrifugally filtering and freeze-drying the enzymolysis product to prepare yak bone collagen peptide; wherein the compound enzyme comprises trypsin, alkaline protease and flavourzyme, and the compound bacteria comprise lactobacillus plantarum and propionibacterium. Lactobacillus plantarum and propionibacterium in the compound bacteria are subjected to synergistic fermentation, and are combined with the enzymolysis reaction of the compound enzyme, so that collagen is decomposed into small molecule peptides more efficiently, the extraction rate of bone collagen peptide is increased, and the bone mineral density is increased.

This invention provides a halogenated compound for 5' end capping of nucleic acids and its applications, the compound being shown in formula (I). This invention also provides the uses and effects of the above-described compound on nucleic acid transcription and expression.

The invention belongs to the technical field of biology, and relates to an escherichia coli engineering strain for producing L-isoleucine through a methyl malic acid way as well as a construction method and application of the escherichia coli engineering strain. According to the invention, Escherichia coli BW25113 is used as a chassis strain, and a methyl malic acid synthase high-activity mutant gene cimA3.7, an isopropyl malic acid isomerase gene GsleuCD, a 3-isopropyl malic acid dehydrogenase gene AfleuB and a leucine dehydrogenase gene Lsleudh are over-expressed; a methyl malic acid absorption protein gene is over-expressed, and a branched chain amino acid transport system is modified to improve the exosome of the L-isoleucine; all methyl malic acid pathway related genes are integrated to a genome of a chassis strain, and a plasmid-free L-isoleucine production strain is constructed; the copy number of a key gene on a genome is optimized, and the yield of the engineering strain L-isoleucine is increased by introducing a non-oxidative glycolysis approach. The yield of the L-isoleucine after the engineering strain is fermented for 34 hours in a fermentation tank is 56.6 g / L.

The invention provides a genetically engineered bacterium, a preparation method thereof and application of the genetically engineered bacterium in synthesis of sclareol. The genetically engineered bacterium comprises a CcLPPS gene derived from Cistanus crenatus, and a CcLPPS gene derived from Cistanus crenatus, the genetically engineered bacterium is selected from yarrowia lipolytica. According to the invention, the stably expressed sclareol efficient de novo synthesis strain is constructed, and no organic reagent or any path intermediate substance is added in the whole fermentation process, so that the production cost is greatly reduced, and the subsequent separation and purification steps are simplified. The engineering yarrowia lipolytica strain provided by the invention is high in production intensity and simple in fermentation process, has a relatively good application prospect, and lays a foundation for producing sclareol by a microbial fermentation method.

The invention belongs to the technical field of immunology, and particularly relates to an anti-IL-6 nano antibody, a recombinant nano antibody, a recombinant vector and application. The anti-IL-6 nano antibody disclosed by the invention comprises a heavy chain variable region containing CDR1, CDR2 and CDR3, and has the functions of identifying and combining IL-6. The invention also discloses a recombinant nano antibody containing the nano antibody, a recombinant vector and a detection agent, and applications of the nano antibody, the recombinant nano antibody, the recombinant vector and the detection agent in preparation of drugs for treating IL-6 related diseases. The nano antibody, the recombinant nano antibody and the recombinant vector provided by the invention can recognize and combine IL-6, and have a potential effect of treating IL-6-related diseases.

The invention belongs to the technical field of biochemical engineering, and provides a method for increasing L-carnosine yield of escherichia coli by increasing PRPP supply, and the yield and yield of L-carnosine are remarkably increased by up-regulating expression of a prs gene, increasing PRPP content in cells and promoting synthesis of L-histidine. Experiments show that the yield of the L-carnosine in different recombinant strains is increased by 55.56%-140%, and L-histidine and beta-alanine do not need to be added in the production process.

To provide antibodies that bind to lymphocyte activation gene 3 (LAG3) protein, which is a T cell co-inhibitor, and methods of use.SOLUTION: In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing means of treating a disease or disorder such as cancer or viral infection. The antibodies of the present invention are useful, inter alia, for targeting immune cells expressing LAG3 and for modulating LAG3 activity.SELECTED DRAWING: None

The invention belongs to the technical field of immunology, and particularly relates to a targeted IL-6 biological nano antibody and application thereof. The invention discloses a nano antibody for targeting IL-6, which comprises a heavy chain variable region containing CDR1, CDR2 and CDR3, and has the functions of identifying and combining IL-6. The invention also discloses a composition containing the nano antibody or the IL-6 binding molecule, and an application of the composition containing the nano antibody and the IL-6 binding molecule in preparation of drugs for treating IL-6 related diseases. The nano antibody, the BCMA binding molecule and the composition can recognize and bind IL-6, and have a potential effect of treating IL-6 related diseases.

The invention discloses two brand-new bioactive peptides with antioxidant and alpha-glucosidase inhibitory activity in traditional Chinese medicine hippocampus. The sequences of the novel bioactive peptides provided by the invention are respectively YLPPNW and SVWLGGSLL. According to the method, purity and structure identification is carried out on the new bioactive peptide obtained through separation by adopting liquid phase, primary mass spectrum and secondary mass spectrum, and a material basis is provided for further quality control and drug effect research of the traditional Chinese medicine hippocampus.

The invention relates to the technical field of biology, in particular to a verticillium dahliae virulence gene, a verticillium dahliae virulence protein and application. The invention discloses a verticillium dahliae virulence gene VdPHO23like. The verticillium dahliae virulence gene VdPHO23like comprises a polynucleotide sequence for coding an amino acid sequence of SEQ ID NO: 3. According to the invention, expression of the gene is inhibited in a targeted manner through an RNA interference mediated gene silencing technology so as to weaken virulence of pathogenic bacteria, and an efficient, specific and environment-friendly comprehensive prevention and control strategy is provided for verticillium wilt of crops such as cotton.

The invention belongs to the technical field of gene engineering, and particularly relates to applications of OpgG and a mutant thereof in production of human milk oligosaccharide. The invention provides a dextran biosynthetic protein OpgG mutant, and the OpgG mutant is obtained by mutating the 443rd amino acid from threonine to proline on the basis of a wild type dextran biosynthetic protein OpgG as shown in SEQ ID NO.1. The invention also provides a preparation method of the dextran biosynthetic protein OpgG mutant. An opgG gene and / or a T443P mutant coding gene are / is introduced into a human milk oligosaccharide production strain and applied to production of human milk oligosaccharide, and the yield of 3 '-SL, 6'-SL, LNT II, LNnT and LNT is greatly increased.

The invention discloses an AsMYB19 gene and application thereof, and relates to the technical field of biology, the nucleotide sequence of the AsMYB19 gene is shown as SEQ ID NO.1, the AsMYB19 gene can regulate and control the tiller number and the yield of oat, gene resources and strategies are provided for oat breeding and improvement of oat germplasm resources, the breeding speed is increased, and the breeding efficiency is improved.

The present invention relates to the fields of genetic engineering and plant genetic breeding, and specifically to the application of wheat TaPND gene. In the present invention, by taking gene TaPND as a target, designing a sgRNA sequence based on CRISPR / Cas9, connecting a DNA fragment containing the encoding sgRNA sequence to a vector carrying CRISPR / Cas, a plant binary expression vector capable of knocking out the TaPND gene in wheat is constructed; by genetically transforming wheat, offspring with TaPND gene knockout are obtained, and wheat mutants with early flowering time are obtained. Experiments have confirmed that transgenic wheat with TaPND gene knockout achieves the advancement of wheat flowering time. The technical scheme of the present invention provides a practical method for realizing rapid wheat breeding using genetic engineering technology, which has important breeding application value and broad market application prospects.